Proactive Investors - Run By Investors For Investors

Major announcements for MaxCyte

MaxCyte Inc (LON:MXCT) has signed a research agreement with Kite Pharma Inc, a subsidiary of US drugmaker Gilead Sciences Inc (NASDAQ:GILD), to use its Flow Electroporation Technology (FET) platform. The AIM-listed bioscience firm said under the agreement Kite would use the FET platform to enable non-viral cell engineering. News here too on MaxCyte's expanded relationship with CRISPR Therapeutics as part of its quest to develop new gene therapies for the treatment of cancer after the pair signed a commercial licence agreement.
Doug Doerfler, MaxCyte Chief Executive, said the agreement was a “validation” of his firm’s technology, while CRISPR boss, Samarth Kulkarni, said he was pleased to have secured access to “the leading ex vivo delivery platform for both clinical and commercial use”.

 
Meet W Resources PLC, Avation PLC, Anglo Asian Mining PLC and Salt Lake Potash Ltd at our event, London , 28 February 2019. Register here »
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use